You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Claims for Patent: 7,135,489

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,135,489

Title:	Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
Abstract:	A stable crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide is described. This crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations.
Inventor(s):	Talley; John J (Brentwood, MO), Medich; John R (Gurnee, IL), McLaughlin; Kathleen T (Arlington Heights, IL), Gaud; Henry T (Evanston, IL), Yonan; Edward E (Carol Stream, IL)
Assignee:	G. D. Searle & Co. (Skokie, IL)
Application Number:	10/205,732
Patent Claims:	1. A crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide having an infrared spectrum with the following peaks 3377, 1170, 1151, 925, 844, 745, 729, and 534 cm.sup.-1. 2. A crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide having an X-ray powder diffraction pattern with peaks at about 12.2, 15.4, 15.8, 17.1, 19.8, 22.0, 23.6, 23.9, and 24.6 degrees two theta. 3. A crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide having an x-ray powder diffraction pattern with the following peaks: 12.221, 15.447, 17.081, 19.798 and 23.861 degrees two theta. 4. A form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide according to claim 2, which has an infrared spectrum lacking a significant peak at 723 cm.sup.-1. 5. A pharmaceutical composition comprising a therapeutically-effective amount of the crystalline form of claim 2. 6. A pharmaceutical composition comprising a therapeutically-effective amount of the crystalline form of claim 2. 7. A crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide having an onset of melting of about 170.9.degree. C. with a peak at about 172.5.degree. C. as determined by differential scanning calorimetry. 8. A crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide having an IR spectrum comprising three peaks selected from 3377, 1170, 1151, 925, 844, 745, 729, and 534 cm.sup.-1. 9. A crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide having an x-ray powder diffraction pattern comprising threee peaks selected from 12.221, 15.447, 17.081, 19.798 and 23.861 degrees 2.theta.. 10. A pharmaceutical composition comprising a therapeutically-effective amount of the crystalline form of claim 8 and at least one pharmaceutically acceptable carrier, adjuvant, or diluent. 11. A pharmaceutical composition comprising a therapeutically-effective amount of the crystalline form of claim 9 and at least one pharmaceutically acceptable carrier, adjutant, or diluent.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.